ArticleThe Journal of experimental medicine2020

KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K-MAPK1 inhibition.

Harish Palleti Janardhan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.